Search

Your search keyword '"Yamamoto, Tomohisa"' showing total 531 results
Start Over Author "Yamamoto, Tomohisa"
531 results on '"Yamamoto, Tomohisa"'

103. Postpancreatectomy hemorrhage

Author

YAMAMOTO, Tomohisa, primary, SATOI, Sohei, additional, YAMAKI, So, additional, HIROOKA, Satoshi, additional, MATSUI, Yoichi, additional, INOUE, Kentaro, additional, and SEKIMOTO, Mitsugu, additional

Published
2019
Full Text
View/download PDF

105. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).

Author

Satoi, Sohei, primary, Unno, Michiaki, additional, Motoi, Fuyuhiko, additional, Matsuyama, Yutaka, additional, Matsumoto, Ippei, additional, Aosasa, Suefumi, additional, Shirakawa, Hirofumi, additional, Wada, Keita, additional, Fujii, Tsutomu, additional, Yoshitomi, Hideyuki, additional, Takahashi, Shinichiro, additional, Sho, Masayuki, additional, Ueno, Hideki, additional, Yamamoto, Tomohisa, additional, and Kosuge, Tomoo, additional

Published
2019
Full Text
View/download PDF

106. Long-term survival of a patient with pancreatic ductal adenocarcinoma with peritoneal dissemination treated with S-1 plus intravenous and intraperitoneal paclitaxel followed by conversion surgery

Author

KOTSUKA, Masaya, primary, SATOI, Sohei, additional, YANAGIMOTO, Hiroaki, additional, YAMAMOTO, Tomohisa, additional, KOSAKA, Hisashi, additional, HIROOKA, Satoshi, additional, YAMAKI, So, additional, MICHIURA, Taku, additional, INOUE, Kentaro, additional, and MATSUI, Yoichi, additional

Published
2019
Full Text
View/download PDF

107. Results of conversion surgery after the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic cancer.

Author

Ikeda, Naoya, primary, Akahori, Takahiro, additional, Satoi, Sohei, additional, Yanagimoto, Hiroaki, additional, Nagai, Minako, additional, Nakagawa, Kenji, additional, Nishiwada, Satoshi, additional, Nakamura, Kota, additional, Takagi, Tadataka, additional, Hirooka, Satoshi, additional, Yamamoto, Tomohisa, additional, Yamaki, So, additional, and Sho, Masayuki, additional

Published
2019
Full Text
View/download PDF

108. 80歳以上の高齢者膵癌に対する膵切除の意義

Author

Kinoshita, Shoichi, Sho, Masayuki, Yanagimoto, Hiroaki, Satoi, Sohei, Akahori, Takahiro, Nagai, Minako, Nishiwada, Satoshi, Yamamoto, Tomohisa, Hirooka, Satoshi, Yamaki, So, Ikeda, Naoya, Kwon, A-Hon, and Nakajima, Yoshiyuki

Subjects
Elderly, Pancreatectomy, Chemotherapy, Surgery, Prognosis, Pancreatic adenocarcinoma
Abstract

Background: There is increasing need to evaluate the surgical indication of pancreatic cancer in very elderly patients. However, the available clinical data are limited, and the optimal treatment is still controversial. The aim of this study was to evaluate the benefit of pancreatic resection in pancreatic cancer patients over the age of 80. Methods: Between 2005 and 2012, 26 octogenarian patients who received pancreatic resection and 20 who received chemotherapy for pancreatic cancer were retrospectively reviewed. Clinicopathological factors, chemotherapy administration status, and survival were compared. Univariate and multivariate analysis of prognostic factors for survival was performed. Results: Postoperative major complication rate was 8%, with no mortality. The one-year survival rate and median survival time of the surgery and chemotherapy groups were 50% and 45%, and 12.4 months and 11.7 months, respectively (P = 0.263). Of the 26 resected cases, 6 completed the planned adjuvant chemotherapy treatment course. The median survival time of those 6 completed cases was significantly longer than that of the 20 not completed cases (23.4 versus 10.0 months, P = 0.034). Furthermore, a multivariate analysis of the 26 resected cases showed that distant metastasis (HR 3.206, 95%CI 1.005-10.22, P = 0.049) and completion of the planned adjuvant therapy (HR 4.078, 95%CI 1.162-14.30, P = 0.028) were independent prognostic factors of surgical resection. Conclusions: Surgical resection was safe, but not superior to chemotherapy for pancreatic cancer in octogenarians. In the very elderly, only selected patients may benefit from pancreatic resection., 博士（医学）・乙第1513号・令和3年12月21日, Copyright © 2015 IAP and EPC. Published by Elsevier, a division of RELX India, Pvt. Ltd. All rights reserved.

Published
2015

109. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.

Author

Ueno, Makoto, Morizane, Chigusa, Okusaka, Takuji, Mizusawa, Junki, Kataoka, Tomoko, Ikeda, Masafumi, Ozaka, Masato, Okano, Naohiro, Sugimori, Kazuya, Todaka, Akiko, Shimizu, Satoshi, Mizuno, Nobumasa, Yamamoto, Tomohisa, Sano, Keiji, Tobimatsu, Kazutoshi, Katanuma, Akio, Miyamoto, Atsushi, Yamaguchi, Hironori, Nishina, Tomohiro, and Shirakawa, Hirofumi

Subjects
CANCER chemotherapy, BILIARY tract cancer, CREATININE, HEMATOLOGY, CISPLATIN, GEMCITABINE
Abstract

JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whether GS can be recommended for patients with low creatinine clearance (CCr). Renal function was classified by CCr as calculated by the Cockcroft-Gault formula: high CCr (CCr ≥ 80 ml/min) and low CCr (80 > CCr ≥ 50 ml/min). Of 354 patients, 87 patients on GC and 91 on GS were included in the low CCr group, while there were 88 patients on GC and 88 patients on GS in the high CCr group. The HR of overall survival for GS compared with GC was 0.687 (95% CI 0.504–0.937) in the low CCr group. Although the total number of incidences of all Grade 3–4 non-haematological adverse reactions was higher (36.0% vs. 11.8%, p = 0.0002), the number of patients who discontinued treatment was not different (14.1% vs. 16.9%, p = 0.679) for GS compared with GC in the low CCr group. This study suggests that GS should be selected for the treatment of advanced BTC patients with reduced renal function. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

110. Clinicopathological features and immune profiles of follicular pancreatitis

Author

Hiroaki Yanagimoto, Mitsuaki Ishida, Yamamoto Tomohisa, Koji Tsuta, Hironori Ryota, Yoichi Matsui, Kazuichi Okazaki, So Yamaki, Hisashi Kosaka, Satoshi Hirooka, Masaya Kotsuka, and Sohei Satoi

Subjects
Pathology, medicine.medical_specialty, Immune system, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Follicular phase, Gastroenterology, Medicine, Pancreatitis, Clinicopathological features, business, medicine.disease
Published
2018
Full Text
View/download PDF

111. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

Author

Akahori, Takahiro, primary, Sho, Masayuki, additional, Yanagimoto, Hiroaki, additional, Satoi, Sohei, additional, Nagai, Minako, additional, Nishiwada, Satoshi, additional, Nakagawa, Kenji, additional, Nakamura, Kota, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, and Ikeda, Naoya, additional

Published
2019
Full Text
View/download PDF

115. Multicenter randomized phase II trial of prophylactic right‐half dissection of superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic head cancer.

Author

Yamada, Suguru, Satoi, Sohei, Takami, Hideki, Yamamoto, Tomohisa, Yoshioka, Isaku, Sonohara, Fuminori, Yamaki, So, Shibuya, Kazuto, Hayashi, Masamichi, Hashimoto, Daisuke, Ando, Masahiko, Murotani, Kenta, Sekimoto, Mitsugu, Kodera, Yasuhiro, and Fujii, Tsutomu

Subjects
RANDOMIZED controlled trials, MESENTERIC veins, PANCREATIC cancer
Abstract

Aim: Right‐half dissection of the superior mesenteric artery (SMA) nerve plexus in pancreatoduodenectomy for pancreatic cancer was initiated to accomplish R0 resection; however, subsequent refractory diarrhea was a major concern. This study aimed to evaluate the necessity of this technique. Methods: From April 2014 to June 2018, 74 patients with pancreatic head cancer were randomly allocated to either Group A, in which right‐half dissection of the SMA nerve plexus was performed (n = 37), or Group B, in which total preservation of the nerve plexus was performed (n = 37). Short‐term, long‐term, and survival outcomes were prospectively compared between the groups. Results: The patient demographics, including the R0 resection rate, were not significantly different between the groups. Postoperative diarrhea occurred in 26 (70.3%) patients in Group A and 18 (48.6%) patients in Group B. There was a tendency for the development of severe diarrhea in Group A within 1 year postoperatively, and the frequency of diarrhea gradually decreased within 2 years, although that did not affect tolerance to adjuvant chemotherapy. There was no difference in either locoregional recurrence (27.0% vs 32.4%) or systemic recurrence (46.0% vs 46.0%). The median overall survival time in Groups A and B was 37.9 and 34.6 months, respectively (P = 0.77). Conclusion: We did not demonstrate a clinical impact of right‐half dissection of the SMA nerve plexus on locoregional recurrence or survival. Therefore, the prophylactic dissection of the SMA nerve plexus is unnecessary given that refractory diarrhea could be induced by this technique (UMIN000012241). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

117. Dual-center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage

Author

Yamamoto, Tomohisa, primary, Satoi, Sohei, additional, Fujii, Tsutomu, additional, Yamada, Suguru, additional, Yanagimoto, Hiroaki, additional, Yamaki, So, additional, Takami, Hideki, additional, Hirooka, Satoshi, additional, Kosaka, Hisashi, additional, Kotsuka, Masaya, additional, Miyara, Takayuki, additional, and Kodera, Yasuhiro, additional

Published
2018
Full Text
View/download PDF

120. Clinical impact of developing better practices at the institutional level on surgical outcomes after distal pancreatectomy in 1515 patients: Domestic audit of the Japanese Society of Pancreatic Surgery

Author

Satoi, Sohei, primary, Yamamoto, Tomohisa, additional, Motoi, Fuyuhiko, additional, Matsumoto, Ippei, additional, Yoshitomi, Hideyuki, additional, Amano, Ryosuke, additional, Tahara, Munenori, additional, Murakami, Yoshiaki, additional, Arimitsu, Hidehito, additional, Hirono, Seiko, additional, Sho, Masayuki, additional, Ryota, Hironori, additional, Ohtsuka, Masayuki, additional, Unno, Michiaki, additional, Takeyama, Yoshifumi, additional, and Yamaue, Hiroki, additional

Published
2018
Full Text
View/download PDF

124. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution

Author

Satoi, Sohei, primary, Yanagimoto, Hiroaki, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Kosaka, Hisashi, additional, Inoue, Kentaro, additional, Hashimoto, Yuki, additional, Matsui, Yoichi, additional, and Kon, Masanori, additional

Published
2017
Full Text
View/download PDF

125. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma.

Author

Satoi, Sohei, Yamamoto, Tomohisa, Yamaki, So, Sakaguchi, Tatsuma, and Sekimoto, Mitsugu

Subjects
ADENOCARCINOMA, SURGICAL indications
Abstract

Aim of this review is to propose an acceptable surgical indication for conversion surgery in patients with initially unresectable (UR) pancreatic ductal adenocarcinoma (PDAC) by considering desirable outcomes, including resectability, overall survival (OS), and disease‐free survival (DFS). A comprehensive literature search of PubMed was conducted through July 15, 2019. Eligible studies were those reporting on patients with UR‐PDAC who underwent surgery. We excluded case reports with fewer than 10 patients, insufficient descriptions of survival data, and palliative surgery. When patients with UR‐PDAC with no progression after chemo(radiation) therapy were offered surgical exploration, resectability and median survival time (MST) of those who underwent conversion surgery ranged from 20% to 69% (median, 52%) and from 19.5 to 33 months (median, 21.9 months), respectively. When conversion surgery was carried out in patients with expected margin‐negative resection or with clinical response by Response Evaluation Criteria In Solid Tumors (RECIST), resectability and MST ranged from 18% to 27% (median, 20%) and from 21 to 35.3 months (median, 30 months), respectively. Among patients who underwent conversion surgery based on clinical response and decreased CA19‐9 level after multimodal treatment, resectability and MST ranged from 2% to 24% (median, 4.1%) and from 24.1 to 64 months (median, 36 months), respectively. Decreased CA19‐9 level was a predictor of resectability, OS and DFS by multivariate analysis. In conclusion, decision‐making for conversion surgery based on clinical response and decreased CA19‐9 level after multimodal treatment may be appropriate. With regard to desirable outcomes of OS and DFS, conversion surgery may provide improved survival for patients with initial UR‐PDAC. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

127. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma

Author

Karabicak, Ilhan, primary, Satoi, Sohei, additional, Yanagimoto, Hiroaki, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Kosaka, Hisashi, additional, Inoue, Kentaro, additional, Matsui, Yoichi, additional, and Kon, Masanori, additional

Published
2016
Full Text
View/download PDF

133. A protective role of pancrelipase delayed-release capsules against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer: A randomized controlled trial

Author

Yanagimoto, Hiroaki, primary, Satoi, Sohei, additional, Sho, Masayuki, additional, Yamamoto, Tomohisa, additional, Akahori, Takahiro, additional, Kinoshita, Shoichi, additional, Nagai, Minako, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Nishiwada, Satoshi, additional, Ryota, Hironori, additional, Ikeda, Naoya, additional, Nakajima, Yoshiyuki, additional, and Kon, Masanori, additional

Published
2016
Full Text
View/download PDF

135. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis

Author

Satoi, Sohei, primary, Murakami, Yoshiaki, additional, Motoi, Fuyuhiko, additional, Sho, Masayuki, additional, Matsumoto, Ippei, additional, Uemura, Kenichiro, additional, Kawai, Manabu, additional, Kurata, Masanao, additional, Yanagimoto, Hiroaki, additional, Yamamoto, Tomohisa, additional, Mizuma, Masamichi, additional, Unno, Michiaki, additional, Kinoshita, Shoichi, additional, Akahori, Takahiro, additional, Shinzeki, Makoto, additional, Fukumoto, Takumi, additional, Hashimoto, Yasushi, additional, Hirono, Seiko, additional, Yamaue, Hiroki, additional, Honda, Goro, additional, and Kwon, Masanori, additional

Published
2016
Full Text
View/download PDF

137. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy

Author

Satoi, Sohei, primary, Yanagimoto, Hiroaki, additional, Yamamoto, Tomohisa, additional, Ohe, Chisato, additional, Miyasaka, Chika, additional, Uemura, Yoshiko, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Ryota, Hironori, additional, Michiura, Taku, additional, Inoue, Kentaro, additional, Matsui, Yoichi, additional, Tanigawa, Noboru, additional, and Kon, Masanori, additional

Published
2016
Full Text
View/download PDF

138. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting

Author

Fujii, Tsutomu, primary, Satoi, Sohei, additional, Yamada, Suguru, additional, Murotani, Kenta, additional, Yanagimoto, Hiroaki, additional, Takami, Hideki, additional, Yamamoto, Tomohisa, additional, Kanda, Mitsuro, additional, Yamaki, So, additional, Hirooka, Satoshi, additional, Kon, Masanori, additional, and Kodera, Yasuhiro, additional

Published
2016
Full Text
View/download PDF

139. Sa1451 Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis

Author

Mizuma, Masamichi, primary, Satoi, Sohei, additional, Fujii, Tsutomu, additional, Yanagimoto, Hiroaki, additional, Kurata, Masanao, additional, Takahara, Naminatsu, additional, Yamada, Suguru, additional, Motoi, Fuyuhiko, additional, Yamamoto, Tomohisa, additional, Honda, Goro, additional, Isayama, Hiroyuki, additional, Ishigami, Hironori, additional, Unno, Michiaki, additional, and Kwon, A-Hon, additional

Published
2016
Full Text
View/download PDF

140. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma

Author

Yanagimoto, Hiroaki, primary, Satoi, Sohei, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Kotsuka, Masaya, additional, Ryota, Hironori, additional, Michiura, Taku, additional, Inoue, Kentaro, additional, Matsui, Yoichi, additional, Tsuta, Koji, additional, and Kon, Masanori, additional

Published
2016
Full Text
View/download PDF

141. Persistent isoflurane-induced hypotension causes hippocampal neuronal damage in a rat model of chronic cerebral hypoperfusion.

Author

Yamamoto, Tomohisa, Iwamoto, Tatsushige, Kimura, Seishi, and Nakao, Shinichi

Subjects
ISOFLURANE, HIPPOCAMPUS (Brain), HYPOTENSION, CEREBRAL infarction, WHITE matter (Nerve tissue), WOUNDS & injuries
Abstract

Background: Postoperative cognitive dysfunction (POCD) is likely to occur in elderly people, who often suffer from cerebral hypoperfusion and white matter lesions even in the absence of cerebral infarctions.Methods: Thirty-two adult male rats were randomly assigned to one of four groups: the cerebral normoperfusion + normotension group (n = 8), cerebral normoperfusion + hypotension group (n = 8), chronic cerebral hypoperfusion (CCH) + normotension group (n = 8), and CCH + hypotension group (n = 8). A rat model of CCH was developed via the permanent ligation of the bilateral common carotid arteries, but ligation was avoided in the cerebral normoperfusion groups. Two weeks later, the rats were intubated and mechanically ventilated under isoflurane anesthesia, and their mean arterial blood pressure was maintained over 80 mmHg (normotension) or below 60 mmHg (hypotension) for 2 h. After preparing brain slices, histological cresyl violet staining, ionized calcium binding adaptor molecule 1, a marker of microglial activation, or β amyloid precursor protein, a marker of axonal damage, were performed.Results and conclusion: CCH per se caused microglial activation and axonal damage, which was not accentuated by hypotension. CCH alone did not cause neuronal damage, but CCH combined with hypotension caused significant neuronal damage in the hippocampal CA1 region. These results suggest that persistent hypotension during general anesthesia might cause neuronal damage in patients with CCH, such as elderly people, and contribute to prevention against POCD. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

142. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma

Author

Yanagimoto, Hiroaki, primary, Satoi, Sohei, additional, Sho, Masayuki, additional, Akahori, Takahiro, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Kotsuka, Masaya, additional, Ryota, Hironori, additional, Kinoshita, Shoichi, additional, Nishiwada, Satoshi, additional, Nagai, Minako, additional, Ikeda, Naoya, additional, Tsuta, Koji, additional, Nakajima, Yoshiyuki, additional, and Kon, Masanori, additional

Published
2015
Full Text
View/download PDF

143. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma

Author

Satoi, Sohei, primary, Yanagimoto, Hiroaki, additional, Yamamoto, Tomohisa, additional, Toyokawa, Hideyoshi, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Opendro, Singh Sapam, additional, Inoue, Kentaro, additional, Michiura, Taku, additional, Ryota, Hironori, additional, Matsui, Yoichi, additional, and Kon, Masanori, additional

Published
2015
Full Text
View/download PDF

145. Potential role of surgical resection for pancreatic cancer in the very elderly

Author

Kinoshita, Shoichi, primary, Sho, Masayuki, additional, Yanagimoto, Hiroaki, additional, Satoi, Sohei, additional, Akahori, Takahiro, additional, Nagai, Minako, additional, Nishiwada, Satoshi, additional, Yamamoto, Tomohisa, additional, Hirooka, Satoshi, additional, Yamaki, So, additional, Ikeda, Naoya, additional, Kwon, A-Hon, additional, and Nakajima, Yoshiyuki, additional

Published
2015
Full Text
View/download PDF

146. Tu1787 Randomized Clinical Trial of Duct-to-Mucosa Pancreaticogastrostomy of Pancreatic Stump Versus Hand-Sewn Closure After Distal Pancreatectomy

Author

Uemura, Kenichiro, primary, Satoi, Sohei, additional, Motoi, Fuyuhiko, additional, Hashimoto, Yasushi, additional, Yanagimoto, Hiroaki, additional, Fukase, Koji, additional, Kondo, Naru, additional, yamamoto, Tomohisa, additional, Katayose, Yu, additional, Kwon, A-Hon, additional, Unno, Michiaki, additional, and Murakami, Yoshiaki, additional

Published
2015
Full Text
View/download PDF

148. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgical group study.

Author

Yamamoto, Tomohisa, Satoi, Sohei, Kawai, Manabu, Motoi, Fuyuhiko, Sho, Masayuki, Uemura, Ken-ichiro, Matsumoto, Ippei, Honda, Goro, Okada, Ken-ichi, Akahori, Takahiro, Toyama, Hirochika, Kurata, Masanao, Yanagimoto, Hiroaki, Yamaue, Hiroki, Unno, Michiaki, Kon, Masanori, and Murakami, Yoshiaki

Abstract

Objectives We retrospectively investigated the operative outcomes of patients who underwent distal pancreatectomy (DP) for invasive pancreatic ductal adenocarcinoma (PDAC) located at the body and tail. Methods Data from 395 patients with PDAC who underwent DP with margin-negative resection (R0 or R1) were collected from seven high-volume centers in Japan from 2001 to 2012. Among them, 72 patients underwent DP with en-bloc celiac axis resection (DP-CAR). The remaining 323 patients underwent conventional DP with splenectomy (DP-S). To determine the efficacy of DP-CAR, clinicopathological data were compared between the DP-CAR and the DP-S groups. Results The DP-S group consisted mainly of patients with resectable disease (93%), and conversely, all patients in the DP-CAR group had borderline resectable or unresectable disease. The overall morbidity was significantly higher in the DP-CAR group than in the DP-S group (63% vs 47%, respectively; P = 0.017). The median survival time (MST) of the DP-CAR group was significantly shorter than that of the DP-S group (17.5 vs 28.6 months, respectively; P = 0.004). However, the MST of patients in the DP-CAR group (n = 61, 85%) who received adjuvant therapy was significantly longer than that of patients in the DP-S group (n = 65, 20%) who underwent R1 resection (21.9 vs 16.7 months, respectively; P = 0.024). Conclusion DP-CAR followed by adjuvant chemotherapy provided an acceptable overall survival rate in patients with highly advanced PDAC, but should be performed with great caution because of high morbidity. Patients with a high risk of positive surgical margins with DP-S may be candidates for DP-CAR. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

149. Clinical effect of pancreaticojejunostomy with a long-internal stent during pancreaticoduodenectomy in patients with a main pancreatic duct of small diameter.

Author

Yamamoto, Tomohisa, Satoi, Sohei, Yanagimoto, Hiroaki, Hirooka, Satoshi, Yamaki, So, Ryota, Hironori, Kotsuka, Masaya, Matsui, Yoichi, and Kon, Masanori

Subjects
PREVENTION of surgical complications, PANCREATIC fistula, PANCREATIC surgery, PANCREATIC duct, SURGICAL stents, PANCREATICODUODENECTOMY, PREVENTION, SURGERY
Abstract

Background: Post-operative pancreatic fistula (POPF) is one of the most common causes of death following pancreaticoduodenectomy (PD). The aim of this study was to evaluate the clinical effect of a long-internal stent on the development of POPF in patients with a main pancreatic duct diameter of 3 mm or less.Study Design: Patients (N = 108) with a main pancreatic duct (≤3 mm) who underwent PD were included in this single-institution historical control study. Between January 2012 and December 2013, 54 patients had undergone PJ with a long-internal stent across the duct-to-mucosa anastomosis (long-stent group), and between February 2009 and December 2011, 54 patients had undergone PJ without a stent (control).Results: There was no significant difference between groups (long-stent vs control) in the incidence of POPF (70% vs. 56%, p = 0.110) and grade B/C POPF (26% vs. 26%, p = 1.000). Univariate analysis identified body mass index, extent of blood loss and soft pancreatic parenchyma as risk factors related to POPF. Multivariate analysis identified extent of blood loss and soft pancreatic parenchyma as significant risk factors.Conclusion: Placement of a long-internal stent during PJ did not reduce POPF after PD in patients with a main pancreatic duct of small diameter. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

150. Comparison of surgical outcomes of three different stump closure techniques during distal pancreatectomy.

Author

Karabicak, Ilhan, Satoi, Sohei, Yanagimoto, Hiroaki, Yamamoto, Tomohisa, Yamaki, So, Kosaka, Hisashi, Hirooka, Satoshi, Kotsuka, Masaya, Michiura, Taku, Inoue, Kentaro, Matsui, Yoichi, and Kon, Masanori

Abstract

Background To find the appropriate method of pancreatic transection during distal pancreatectomy (DP), we retrospectively compared post-operative complications including postoperative pancreatic fistula (POPF) according to the different types of pancreatic transection. Methods This study included 169 patients who underwent pancreatic transection using an ultrasonic activated device (USAD) with transfixion of the pancreatic duct (DP-TF group, n = 89), USAD followed by pancreaticogastrostomy (DP-PG group, n = 44), and a reinforced linear tristapler (DP-ST, n = 36). Results Overall and POPF-related complications in DP-PG group, and delayed gastric emptying (DGE) in DP-ST group were significantly lower than DP-TF group. There were no significant difference in overall complication, length of hospitalization and operative costs between DP-PG and DP-ST groups. Operative time was significantly longer in DP-PG group than others. Conclusion Both DP-PG and DP-ST are associated with better surgical outcomes. Regarding ease of surgical technique, shorter operative times, and similar medical costs, DP with a reinforced linear tristapler is a good choice during DP. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results